



ASX Release

10 October 2018

**ZELDA THERAPEUTICS LIMITED**  
ACN 103 782 378

Level 26  
140 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
enquiries@zeldatherapeutics.com  
www.zeldatherapeutics.com

**Contacts:**

**Zelda Therapeutics**

Dr Richard Hopkins  
Managing Director  
+61 405 656 868  
rhopkins@zeldatherapeutics.com

Monsoon Communications  
Rudi Michelson  
+61 3 9620 3333  
rudim@monsoon.com

**Directors**

Dr Richard Hopkins  
Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

**Tickers:**

Australia (ASX): ZLD  
USA (OTCQB): ZLDAF

**Ordinary Shares:**

755,341,934

**Options:**

49,000,000

1,500,000 (\$0.04 – 6/2/2020)  
\*4,500,000 (\$0.04 – 6/2/2020)  
1,000,000 (\$0.125 – 22/8/2021)  
\*2,000,000 (\$0.125 – 22/8/2021)

40,000,000 (\$0.03125 – 17/11/2021)  
\* subject to vesting conditions

## US Autism Observational Study Underway

- Autism observational trial in USA is underway with 15 patients now formally enrolled in the study
- Study being conducted at Children’s Hospital of Philadelphia (CHOP)
- Paediatric patients already being treated with medicinal cannabis formulations will be monitored
- Preliminary results expected first half of 2019

Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, “Zelda”) is pleased to announce that recruitment has commenced for its autism observational trial, which is being conducted at Children’s Hospital of Philadelphia (CHOP) in the USA. Preliminary results are expected in the first half of 2019.

This trial is seeking to better understand the efficacy of medicinal cannabis treatment in existing patients and will work closely with patient advocacy groups.

This study will utilise CHOP’s extensive research infrastructure and is designed to capture a number of key efficacy and safety measures, including clinical pharmacological data using a novel micro-sampling technique developed by CHOP.

This initial study will lay the groundwork for a possible future clinical trial to generate high quality, robust and acceptable data to validate the existing anecdotal data amongst patient populations.

The ultimate goal is to identify cannabinoid-based compounds that may demonstrate efficacy in the treatment of pediatric autism.

**Dr Richard Hopkins, Managing Director of Zelda said,**

*“We are very excited to have this study underway and to be working alongside CHOP to conduct one of the first formal, robust studies of its type in the world. With studies showing that around 1 in 100 people have autism and with diagnosis rates on the rise, we’re focussed on addressing a major unmet need for potential new therapies to help treat this condition.”*

**Tim Slate**  
**Company Secretary**

## **About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-armed strategy comprising:

- A **human clinical trial programme** focused on insomnia and autism with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.